Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Io Biotech Aps has 3 pending office actions in Biotechnology & Pharmaceuticals. Each matter is associated with a distinct examiner and a distinct art unit, so the workload is distributed across separate examination channels.
BERKE-SCHLESSEL, DAVID W is the busiest examiner, with 1 pending matter. Counsel should coordinate the portfolio’s biotechnology positions while preparing matter-specific responses for each examiner and art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (67%) |
| Double-patenting + other | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BERKE-SCHLESSEL, DAVID W | 1 | 66.8% | +31.5% |
| JOHANSEN, PETER N. | 1 | 59.6% | +24.4% |
| HOPKINS, SAMANTHA LAKE | 1 | 60.7% | +61.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18935162 | ARGINASE1 POLYPEPTIDES | BERKE-SCHLESSEL, DAVID W | — |
| 17616382 | TGF-BETA VACCINE | HOPKINS, SAMANTHA LAKE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18935162 | ARGINASE1 POLYPEPTIDES | BERKE-SCHLESSEL, DAVID W | — |
| 18550854 | COMBINATION THERAPY FOR CANCER | JOHANSEN, PETER N. | — |
| 17616382 | TGF-BETA VACCINE | HOPKINS, SAMANTHA LAKE | — |
| Art Unit | Apps |
|---|---|
| 1651 | 1 |
| 1644 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18935162 | ARGINASE1 POLYPEPTIDES | BERKE-SCHLESSEL, DAVID W | 1651 | §101§112Other | Non-Final OA | — | Pending | Nov 01, 2024 |
| 18550854 | COMBINATION THERAPY FOR CANCER | JOHANSEN, PETER N. | 1644 | §102§103DP | Non-Final OA | — | Pending | Sep 15, 2023 |
| 17616382 | TGF-BETA VACCINE | HOPKINS, SAMANTHA LAKE | 1641 | §101§102§103§112 | Non-Final OA | — | Pending | Dec 03, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialIo Biotech Aps has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
David W Berke-Schlessel has the most, with 1 of Io Biotech Aps's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
